Project background

AMD is a multifactorial disease that progresses with age. It affects day-to-day life due to blurred or reduced central vision. The current treatments can only maintain the state of vision at which it is diagnosed, but painful injections and frequent visits to the eye doctor are part of that. It could worsen with time and restoring vision is a big challenge in the case of AMD, making it one of the leading causes of blindness in the world.

This project will explore the mechanism of action of glatiramer in retinal damage repair, its effect on choroidal neovascularization, and the immune system in an animal model. It will contribute hugely towards our understanding of the pathogenesis of wet AMD and the role played by the immune system in potentially counteracting this progression. The data generated from this study will provide an insight into curing AMD.

Funding

The project is funded by the Irish Research Council under the Enterprise partnership scheme with Experimentica Ltd, Finland.

Teaching Assistant/Lab Supervisor

Module 1: Advanced Techniques in Pharmaceutical Science

Module 2: Pharmaceutical Biotechnology

Neurodegeneration

Immunology

Aging

Inflammation